

Publikationsverzeichnis Andreas Günther

Stand Juni 2017

149 Originalartikel (*peer reviewed*; 51 hiervon als Erst- oder Seniorautor)

3 Korrespondenz/Letters to the Editor

47 Reviews/Editorials/Kommentare (39 als Erst- oder Seniorautor)

13 Buchbeiträge (11 als Erst- oder Seniorautor)

4 Lehrbuchkapitel

Originalartikel (insgesamt 149, 51 Erst- oder Seniorautorenschaften)

- 1) Seeger W, Thede C, **Günther A**, Grube C. Surface properties and sensitivity to protein-inhibition of a recombinant apoprotein C-based phospholipid mixture in vitro - comparison to natural surfactant. [Biochim et Biophys Acta](#) 1081:45-52, 1991. IF 2,557
- 2) Seeger W, **Günther A**, Thede C. Differential sensitivity to fibrinogen-inhibition of SP-C versus SP-B based surfactants. [Am J Physiol Lung Cell Mol Physiol](#) 262:L286-L291, 1992. IF 4,214
- 3) **Günther A**, Bleyl H, Seeger W. Apoprotein-based synthetic surfactants inhibit plasmic cleavage of fibrinogen in vitro. [Am J Physiol Lung Cell Mol Physiol](#) 265:L186-192, 1993. IF 4,214
- 4) Seeger W, Elssner A, **Günther A**, Krämer HJ, Kalinowski HO. Lung surfactant phospholipids associate with polymerizing fibrin - loss of surface activity. [Am J Respir Cell Mol Biol](#) 9:213-220, 1993. IF 4,608
- 5) Seeger W, Grube C, **Günther A**. Proteolytic cleavage of fibrinogen: Amplification of its surfactant inhibitory capacity. [Am J Respir Cell Mol Biol](#) 9:239-247, 1993. IF 4,608
- 6) Seeger W, Grube C, **Günther A**, Schmidt R. Surfactant inhibition by plasma proteins: differential sensitivity of various surfactant preparations. [Eur Respir J](#) 6:971-977, 1993. IF 5,349
- 7) **Günther A**, Kalinowski M, Elssner A, Seeger W. Clot embedded natural surfactant: kinetics of fibrinolysis and surface activity. [Am J Physiol Lung Cell Mol Physiol](#) 267:L618-624, 1994. IF 4,214
- 8) Schröder C, **Günther A**, Seeger W, Voelter W. Synthesis and studies on the biophysical activity of human lung surfactant peptide SP-C and its n-terminal fragments. [Biomed Pept Proteins Nucleic Acids](#) 1:13-16, 1994.
- 9) **Günther A**, Kalinowski M, Rousseau S, Seeger W. Surfactant incorporation markedly alters mechanical properties of a fibrin clot. [Am J Respir Cell Mol Biol](#) 13:712-718, 1995. IF 4,608
- 10) Krämer HJ, Schmidt R, **Günther A**, Becker G, Suzuki Y, Seeger W. Elisa technique for quantification of surfactant protein B (SP-B) in bronchoalveolar lavage fluid. [Am J Respir Crit Care Med](#) 152:1540-1544, 1995. IF 9,074
- 11) **Günther A**, Siebert C, Schmidt R, Ziegler S, Grimminger F, Yabut M, Temmesfeld B, Walmrath D, Morr H, Seeger W. Surfactant alterations in severe pneumonia, ARDS and cardiogenic lung edema. [Am J Respir Crit Care Med](#) 153:176-184, 1996. IF 9,074
- 12) Walmrath D, **Günther A**, Schermuly RT, Schneider T, Grimminger F, Seeger W. Bronchoscopic surfactant administration in severe adult respiratory distress syndrome (ARDS). [Am J Respir Crit Care Med](#) 154:57-62, 1996. IF 9,074
- 13) Schermuly RT, Schmehl T, **Günther A**, Grimminger F, Seeger W, Walmrath D. Ultrasonic nebulization for efficient delivery of surfactant in a model of acute lung injury. [Am J Respir Crit Care Med](#) 156:445-453, 1997. IF 9,074

- 14) Rosseau S, **Günther A**, Seeger W, Lohmeyer J. Phagocytosis of viable candida albicans by alveolar macrophages: lack of opsonin function of surfactant protein A. [J Infect Dis](#) 175:421-428, 1997. IF 6,035
- 15) Kiss L, Bieneck E, Weissmann N, Schütte H, Sibelius U, **Günther A**, Bier J, Mayer K, Hennking K, Padberg W, Grimm H, Seeger W, Grimminger F. Simultaneous analysis of 4- and 5- series lipoxygenase and cytochrome P450 products from different biological sources by reversed-phase high-performance liquid chromatographic technique. [Anal Biochem](#) 261:16-18, 1998. IF 3,002
- 16) **Günther A**, Schmidt R, Nix F, Yabut-Perez M, Guth C, Rosseau S, Siebert C, Grimminger F, Morr H, Velcovsky HG, Seeger W. Surfactant abnormalities in idiopathic pulmonary fibrosis, hypersensitivity pneumonitis and sarcoidosis. [Eur Respir J](#) 14:565-573, 1999. IF 5,349
- 17) Steiner D, Bachmann G, **Günther A**, Bauer R. Intrathoracic Goiter. [Clin Nucl Med](#) 24:461-463, 1999. IF 3,231
- 18) **Günther A**, Schmidt R, Feustel A, Meier U, Pucker C, Ermert M, Seeger W. Surfactant subtype conversion is related to loss of Surfactant Apoprotein B and surface activity in the large surfactant aggregates - experimental and clinical studies. [Am J Respir Crit Care Med](#) 159:244-251, 1999. IF 9,074
- 19) **Günther A**, Markart P, Kalinowski M, Ruppert C, Grimminger F, Seeger W. Cleavage of surfactant-incorporating fibrin by different fibrinolytic agents: kinetics of lysis and rescue of surface activity. [Am J Respir Cell Mol Biol](#) 21:738-745, 1999. IF 4,608
- 20) Rosseau S, Hammerl P, Maus U, **Günther A**, Seeger W, Lohmeyer J. Surfactant protein A down-regulates proinflammatory cytokine production evoked by Candida albicans in human alveolar macrophages and monocytes. [J Immunol](#) 163:4495-4502, 1999. IF 6,068
- 21) **Günther A**, Mosavi P, Heinemann S, Ruppert C, Muth H, Markart P, Grimminger F, Walmrath D, Temmesfeld-Wollbrück B, Seeger W. Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia – comparison with the Acute Respiratory Distress Syndrome. [Am J Respir Crit Care Med](#) 161:454-462, 2000. IF 9,074
- 22) **Günther A**, Mosavi P, Ruppert C, Heinemann S, Temmesfeld B, Velcovsky HG, Morr H, Grimminger F, Walmrath D, Seeger W. Enhanced tissue factor pathway activity and fibrin turnover in the alveolar compartment of patients with interstitial lung disease. [Thromb Haemost](#) 83:853-860, 2000. IF 3,501
- 23) Schermuly RT, **Günther A**, Weissmann N, Ghofrani HA, Seeger W, Grimminger F, Walmrath D. Differential Impact of ultrasonically nebulized versus tracheal-instilled surfactant on ventilation-perfusion (VA/Q) mismatch in a model of acute lung injury. [Am J Respir Crit Care Med](#) 161:152-159, 2000. IF 9,074
- 24) Schmidt R, Meier U, Yabut-Perez M, Walmrath D, Grimminger F, Seeger W, **Günther A**. Alteration of fatty acid profiles in different pulmonary surfactant phospholipids in acute respiratory distress syndrome (ARDS) and severe pneumonia. [Am J Respir Crit Care Med](#) 163:95-100, 2001. IF 9,074
- 25) Schermuly RT, **Günther A**, Ermert M, Ermert L, Ghofrani HA, Weissmann N, Grimminger F, Seeger W, Walmrath D. Co-nebulization of surfactant and urokinase restores gas exchange in perfused lungs with alveolar fibrin formation. [Am J Physiol Lung Cell Mol Physiol](#) 280:L792-L800, 2001. IF 4,214
- 26) Friedrich I, Spillner J, Lu EX, Bartling B, Barnscheid M, Sablotzki A, Schade U, Reidemeister JC, Silber RE, **Günther A**, Borgermann J. Ischemic preconditioning of 5 minutes but not of 10 minutes improves lung function after warm ischemia in a canine model. [J Heart Lung Transplant](#) 20:985-995, 2001. IF 3,087
- 27) Schmidt R, Steinhilber W, Ruppert C, Daum C, Grimminger F, Seeger W, **Günther A**. An ELISA technique for quantification of surfactant apoprotein (SP)-C in bronchoalveolar lavage fluid. [Am J Respir Crit Care Med](#) 165:470-474, 2002. IF 9,074

- 28) Ermert M, Ruppert C, **Günther A**, Duncker HR, Seeger W, Ermert L. Cell-specific nitric oxide synthase-isoenzyme expression and regulation in response to endotoxin in intact rat lungs. [Lab Invest](#) 82:425-441, 2002. IF 4,479
- 29) **Günther A**, Schmidt R, Harodt J, Schmehl T, Walmrath D, Ruppert C, Grimminger F, Seeger W. Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact on biophysical and biochemical surfactant properties. [Eur Respir J](#) 19:797-804, 2002. IF 5,349
- 30) Walmrath D, Grimminger F, Pappert D, Knothe C, Obertacke U, Benzing A, **Günther A**, Schmehl T, Leuchte H, Seeger W. Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact on gas exchange and haemodynamics. [Eur Respir J](#) 19:805-810, 2002. IF 5,349
- 31) Ruppert C, Schmidt R, Grimminger F, Suzuki Y, Seeger W, Lehr CM, **Günther A**. Chemical coupling of a monoclonal antisurfactant protein-B antibody to human urokinase for targeting surfactant-incorporating alveolar fibrin. [Bioconjug Chem](#) 13:804-811, 2002. IF 4,384
- 32) Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, **Günther A**, Walmrath D, Seeger W, Grimminger F. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. [Lancet](#) 360:895-900, 2002. IF 28,638
- 33) Schmidt R, Meier U, Markart P, Grimminger F, Velcovsky HG, Morr H, Seeger W, **Günther A**. Altered fatty acid composition of lung surfactant phospholipids in interstitial lung disease. [Am J Physiol Lung Cell Mol Physiol](#) 283:L1079-L1085, 2002. IF 4,214
- 34) Markart P, Ruppert C, Grimminger F, Seeger W, **Günther A**. Fibrinolysis-inhibitory capacity of clot-embedded surfactant is enhanced by SP-B and SP-C. [Am J Physiol Lung Cell Mol Physiol](#) 284:L69-L76, 2003. IF 4,214
- 35) Weissmann N, Nollen M, Gerigk B, Ghofrani HA, Schermuly RT, **Günther A**, Quanz K, Fink L, Hänze J, Rose F, Seeger W, Grimminger F. Downregulation of hypoxic vasoconstriction by chronic hypoxia in rabbits: effects of nitric oxide. [Am J Physiol Heart Circ Physiol](#) 284:H931-H938, 2003. IF 3,973
- 36) Ruppert C, Pucker C, Markart P, Schmidt R, Grimminger F, Seeger W, Stürzebecher J, **Günther A**. Selective inhibition of large-to-small surfactant aggregate conversion by serine protease inhibitors of the bis-benzamidine type. [Am J Respir Cell Mol Biol](#) 28:95-102, 2003. IF 4,608
- 37) Ruppert C, Markart P, Schmidt R, Grimminger F, Seeger W, Lehr CM, **Günther A**. Chemical crosslinking of urokinase to pulmonary surfactant protein B for targeting alveolar fibrin. [Thromb Haemost](#) 89:53-64, 2003. IF 3,501
- 38) Friedrich B, Schmidt R, Reiss I, **Günther A**, Seeger W, Müller M, Thul J, Schranz D, Gortner L. Changes in biochemical and biophysical surfactant properties with cardiopulmonary bypass in children. [Crit Care Med](#) 31:284-290, 2003. IF 6,285
- 39) Ruppert C, Pucker C, Markart P, Seibold K, Bagheri A, Grimminger F, Seeger W, **Günther A**. Impact of surface tension on the conversion rate of large to small surfactant aggregates. [Biophys Chem](#) 104:229-238, 2003. IF 1,784
- 40) Hilgendorff A, Rawer D, Doerner M, Tutdibi E, Ebsen M, Schmidt R, **Günther A**, Gortner L, Reiss I. Synthetic and natural surfactant differentially modulate inflammation after meconium aspiration. [Intens Care Med](#) 29:2247-2254, 2003. IF 4,406
- 41) **Günther A**, Lübke N, Ermert M, Schermuly RT, Weissmann N, Breithecker A, Markart P, Ruppert C, Quanz K, Ermert L, Grimminger F, Seeger W. Prevention of bleomycin-induced lung fibrosis by aerosolization of heparin or urokinase in rabbits. [Am J Respir Crit Care Med](#) 168:1358-1365, 2003. IF 9,074

- 42) Schermuly RT, Kreisselmeier KP, Ghofrani HA, Yilmaz H, Butrous G, Ermert L, Ermert M, Weissmann N, Rose F, **Günther A**, Walmrath D, Seeger W, Grimminger F. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. [Am J Respir Crit Care Med](#) 169:39-45, 2004. IF 9,074
- 43) Muth H, Maus U, Wygrecka M, Lohmeyer J, Grimminger F, Seeger W, **Günther A**. Pro- and antifibrinolytic properties of human pulmonary microvascular versus artery endothelial cells: impact of endotoxin and tumor necrosis factor-alpha. [Crit Care Med](#) 32:217-226, 2004. IF 6,285
- 44) Schmidt R, Schäfer C, Luboeinski T, Lockinger A, Hermle G, Grimminger F, Seeger W, Ghofrani HA, Schutte H, **Günther A**. Increase in alveolar antioxidant levels in hyperoxic and anoxic ventilated rabbit lungs during ischemia. [Free Radic Biol Med](#) 36:78-89, 2004. IF 4,813
- 45) Schmidt R, Luboeinski T, Markart P, Ruppert C, Daum C, Grimminger F, Seeger W, **Günther A**. Alveolar antioxidant status in patients with acute respiratory distress syndrome. [Eur Respir J](#) 24:994-999, 2004. IF 5,349
- 46) Friedrich I, Borgermann J, Splittgerber FH, Brinkmann M, Reidemeister JC, Silber RE, Seeger W, Schmidt R, **Günther A**. Bronchoscopic surfactant administration preserves gas exchange and pulmonary compliance after single lung transplantation in dogs. [J Thorac Cardiovasc Surg](#) 127:335-343, 2004. IF 3,354
- 47) **Günther A**, Balsler M, Schmidt R, Markart P, Olk A, Borgermann J, Splittgerber FH, Seeger W, Friedrich I. Surfactant abnormalities after single lung transplantation in dogs: impact of bronchoscopic surfactant administration. [J Thorac Cardiovasc Surg](#) 127:344-354, 2004. IF 3,354
- 48) Schmidt R, Ruppert C, Markart P, Lübke N, Ermert L, Weissmann N, Breithecker A, Ermert M, Seeger W, **Günther A**. Changes in pulmonary surfactant function and composition in bleomycin-induced pneumonitis and fibrosis. [Toxicol Appl Pharmacol](#) 195:218-231, 2004. IF 3,846
- 49) Wygrecka M, Markart P, Ruppert C, Kuchenbuch T, Fink L, Bohle R, Grimminger F, Seeger W, **Günther A**. Compartment- and cell-specific expression of coagulation and fibrinolysis factors in the murine lung undergoing inhalative versus intravenous endotoxin application. [Thromb Haemost](#) 92:529-540, 2004. IF 3,501
- 50) Frerking I, Sengler C, **Günther A**, Walmrath D, Stevens P, Witt H, Landt O, Pison U, Nickel R. Evaluation of the -26G>A CC16 polymorphism in acute respiratory distress syndrome. [Crit Care Med](#) 33:2404-2406, 2005. IF 6,285
- 51) Greschus S, Kiessling F, Lichy MP, Moll J, Mueller M, Savai R, Rose F, Ruppert C, **Günther A**, Fusenig N, Semmler W, Traupe H. Potential applications of flat-panel volumetric CT in morphological and functional small animal imaging. [Neoplasia](#) 7:730-740, 2005. IF 5,674
- 52) Markart P, Schmidt R, Ruppert C, Hores C, Silber RE, Borgermann J, **Günther A**, Friedrich I. Ischemic and endotoxin pre-conditioning reduce lung reperfusion injury-induced surfactant alterations. [J Heart Lung Transplant](#) 24:1680-1689, 2005. IF 3,087
- 53) Hilgendorff A, Doerner M, Rawer D, Leick J, Trotter A, Ebsen M, Ruppert C, **Günther A**, Gortner L, Reiss I. Effects of a recombinant surfactant protein-C-based surfactant on lung function and the pulmonary surfactant system in a model of meconium aspiration syndrome. [Crit Care Med](#) 34:203-210, 2006. IF 6,285
- 54) Hilgendorff A, Reiss I, Ruppert C, Hanfstingl T, Seliger AS, **Günther A**, Ebsen M, Gortner L. Positive end-expiratory pressure modifies response to recombinant and natural exogenous surfactant in ventilated immature newborn rabbits. [Biol Neonate](#) 90:210-216, 2006. IF 1,904
- 55) Erpenbeck VJ, Schmidt R, **Günther A**, Krug N, Hohlfeld JM. Surfactant protein levels in bronchoalveolar lavage after segmental allergen challenge in patients with asthma. [Allergy](#) 61:598-604, 2006. IF 5,014
- 56) Schmidt R, Markart P, Ruppert C, Temmesfeld B, Nass R, Lohmeyer J, Seeger W, **Günther A**. Pulmonary Surfactant in Patients with Pneumocystis Pneumonia and Acquired Immunodeficiency Syndrome. [Crit Care Med](#) 34:2370-2376, 2006. IF 6,285

- 57) Ruppert C, Bagheri A, Markart P, Schmidt R, Seeger W, **Günther A**. Liver carboxylesterase cleaves surfactant protein (SP-) B and promotes surfactant subtype conversion. [Biochem Biophys Res Comm](#) 348:1449-1454, 2006. IF 2,749
- 58) Bulau P, Zakrzewicz D, Kitowska K, Leiper J, **Günther A**, Grimminger F, Eickelberg O. Analysis of methylarginine metabolism in the cardiovascular system identifies the lung as a major source of ADMA. [Am J Physiol Lung Cell Mol Physiol](#) 292:L18-L24, 2007. IF 4,214
- 59) Markart P, Ruppert C, Wygrecka M, Schmidt R, Korfei M, Harbach H, Theruvath I, Pison U, Seeger W, **Günther A***, Witt H*. Surfactant protein C mutations in sporadic forms of idiopathic interstitial pneumonias. [Eur Respir J](#) 29:134-137, 2007. IF 5,349
- 60) **Günther A**, Enke B, Markart P, Hammerl P, Morr H, Behr J, Stähler G, Seeger W, Grimminger F, Leconte I, Roux S, Ghofrani HA. Safety and Tolerability of bosentan in Idiopathic Pulmonary Fibrosis: an open label study. [Eur Respir J](#) 29:713-719, 2007. IF 5,349
- 61) Wygrecka M, Markart P, Ruppert C, Petri K, Preissner KT, Seeger W, **Günther A**. Cellular origin of procoagulant and (anti)-fibrinolytic factors in bleomycin-injured lungs. [Eur Respir J](#) 29:1105-1114, 2007. IF 5,349
- 62) Kannemeier C, Shibamiya A, Nakazawa F, Trusheim H, Ruppert C, Markart P, Song Y, Tzima E, Kennerknecht E, Niepmann M, von Bruehl ML, Sedding D, Massberg S, **Günther A**, Engelmann B, Preissner KT. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. [Proc Natl Acad Sci USA](#) 104:6388-6393, 2007. IF 9,598
- 63) Markart P, Ruppert C, Wygrecka M, Colaris T, Dahal B, Walmrath D, Harbach H, Wilhelm J, Seeger W, Schmidt R, **Günther A**. Patients with ARDS show improvement but not normalisation of alveolar surface activity with surfactant treatment: putative role of neutral lipids. [Thorax](#) 62:588-594, 2007. IF 6,226
- 64) Schmidt R, Markart P, Ruppert C, Walmrath D, Seeger W, **Günther A**. Time-dependent changes in pulmonary surfactant function and composition in acute respiratory distress syndrome due to pneumonia or aspiration. [Respir Res](#) 8:55, 2007. IF 3,622
- 65) Wygrecka M, Morty RE, Markart P, Kanse SM, Andreasen PA, Wind T, **Günther A**, Preissner KT. Plasminogen activator inhibitor-1 is an inhibitor of factor VII-activating protease in patients with acute respiratory distress syndrome. [J Biol Chem](#) 282:21671-21682, 2007. IF 5,581
- 66) Wygrecka M, Markart P, Fink L, **Günther A**, Preissner KT. Raised protein levels and altered cellular expression of factor VII-activating protease (FSAP) in the lungs of patients with acute respiratory distress syndrome (ARDS). [Thorax](#) 62:880-888, 2007. IF 6,226
- 67) Königshoff M, Wilhelm A, Jahn A, Sedding D, Amarie OV, Eul B, Seeger W, Fink L, **Günther A**, Eickelberg O, Rose F. The angiotensin II receptor 2 is expressed and mediates angiotensin II signaling in lung fibrosis. [Am J Respir Cell Mol Biol](#) 37:640-650, 2007. IF 4,608
- 68) Sadovski J, Kuchenbuch T, Ruppert C, Fehrenbach A, Hirschburger M, Padberg W, **Günther A**, Hohlfeld JM, Fehrenbach H, Grau V. Keratinocyte growth factor prevents intra-alveolar oedema in experimental lung isografts. [Eur Respir J](#) 31:21-28, 2008. IF 5,545
- 69) Taut F, Rippin G, Schenk P, Findlay G, Wurst W, Häfner D, Lewis JF, Seeger W, **Günther A**, Spragg RG. A search for subgroups of patients with ARDS who may benefit from surfactant replacement therapy: a pooled analysis of five studies with recombinant surfactant protein-C surfactant (Venticute). [Chest](#) 134:724-732, 2008. IF 5,154
- 70) Korfei M, Ruppert C, Mahavadi P, Henneke I, Markart P, Koch M, Lang G, Fink L, Bohle RM, Seeger W, Weaver TE, **Günther A**. Epithelial endoplasmic reticulum stress and apoptosis in sporadic idiopathic pulmonary fibrosis. [Am J Respir Crit Care Med](#) 178:838-846, 2008. IF 9,792
- 71) Schaefer MB, Pose A, Ott J, Hecker M, Behnk A, Schulz R, Weissmann N, **Günther A**, Seeger W, Mayer K. Peroxisome proliferator-activated receptor-alpha reduces inflammation and vascular leakage in a murine model of acute lung injury. [Eur Respir J](#) 32:1344-1353, 2008. IF 5,545

- 72) Hilgendorff A, Aslan E, Schaible T, Gortner L, Baehner T, Ebsen M, Kreuder J, Ruppert C, **Günther A**, Reiss I. Surfactant replacement and open lung concept - comparison of two treatment strategies in an experimental model of neonatal ARDS. [BMC Pulm Med](#) 8:10, 2008.
- 73) Ruppert C, Mahavadi P, Wygrecka M, Weaver T, Magdolen V, Idell S, Preissner KT, Seeger W, **Günther A***, Markart P*. Recombinant production of a hybrid plasminogen activator composed of surfactant protein B and low-molecular-weight urokinase. [Thromb Haemost](#) 100:1185-1192, 2008. IF 3,803
- 74) Markart P, Luboinski T, Korfei M, Schmidt R, Wygrecka M, Mahavadi P, Mayer K, Wilhelm J, Seeger W, **Günther A***, Ruppert C*. Alveolar oxidative stress is associated with elevated levels of non-enzymatic low-molecular-weight antioxidants in patients with different forms of chronic fibrosing interstitial lung diseases. [Antioxid Redox Signal](#) 11:227-240, 2009. IF 7,581
- 75) Mayer K, Kiessling A, Ott J, Schaefer MB, Hecker M, Henneke I, Schulz R, **Günther A**, Wang J, Wu L, Roth J, Seeger W, Kang JX. Acute lung injury is reduced in *fat-1* mice endogenously synthesizing n-3 fatty acids. [Am J Respir Crit Care Med](#) 179:474-483, 2009. IF 10,689
- 76) Königshoff M, Kramer M, Balsara N, Wilhelm J, Amarie OV, Jahn A, Rose F, Fink L, Seeger W, Schaefer L, **Günther A**, Eickelberg O. WNT1-inducible signaling protein-1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis. [J Clin Invest](#) 119:772-787, 2009. IF 15,387
- 77) Wygrecka M, Marsh LM, Morty RE, Henneke I, **Günther A**, Lohmeyer J, Markart P, Preissner KT. Enolase-1 promotes plasminogen-mediated recruitment of monocytes to the acutely inflamed lung. [Blood](#) 113:5588-5598, 2009. IF 10,555
- 78) Woyda K, Koebrich S, Reiss I, Rudloff S, Pullamsetti SS, Rühlmann A, Weissmann N, Ghofrani HA, **Günther A**, Seeger W, Grimminger F, Morty RE, Schermuly RT. Inhibition of phosphodiesterase 4 enhances lung alveolarization in neonatal mice exposed to hyperoxia. [Eur Respir J](#) 33:861-870, 2009. IF 5,527
- 79) Kolosionek E, Savai R, Ghofrani HA, Weissmann N, Grimminger F, Seeger W, Banat GA, **Günther A**, Schermuly RT, Pullamsetti SS. Expression and activity of phosphodiesterase isoforms during epithelial mesenchymal transition. [Mol Biol Cell](#) 20(22):4751-65, 2009. IF 5,979
- 80) Gupte VV, Ramasamy SK, Reddy R, Lee J, Weinreb PH, Violette SM, **Günther A**, Warburton D, Driscoll B, Minoo P, Bellusci S. Overexpression of fibroblast growth factor-10 during both inflammatory and fibrotic phases attenuates bleomycin-induced pulmonary fibrosis in mice. [Am J Respir Crit Care Med](#) 180(5):424-436, 2009. IF 10,689
- 81) Merline R, Lazaroski S, Babelova A, Tsalastra-Greul W, Pfeilschifter J, Schluter KD, **Günther A**, Iozzo RV, Schäfer RM, Schäfer L. Decorin Deficiency in diabetic mice: Aggravation of nephropathy due to overexpression of profibrotic factors, enhanced apoptosis and mononuclear cell infiltration. [J Physiol Pharma](#) 60:5-13, 2009. IF 1,489
- 82) Udalov SB, Dumitrascu R, Pullamsetti SS, Weissman N, Ghofrani HA, **Günther A**, Voswinckel R, Seeger W, Grimminger F, Schermuly RT. Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice. [BMC Pulm Med](#) 10:26, 2010.
- 83) Henneke I, Korfei M, Greschus S, Markart P, Schermuly RT, Wygrecka M, Stürzebecher J, Seeger W, **Günther A***, Ruppert C*. Inhibition of urokinase activity reduces primary tumor growth and metastasis formation in a murine lung carcinoma model. [Am J Respir Crit Care Med](#) 181(6):611-619, 2010. IF 10,191
- 84) Markart P, Nass R, Ruppert C, Hundack L, Wygrecka M, Heinemann S, Korfei M, Boedeker R, Staehler G, Kroll H, Walmrath D, Scheuch G, Preissner KT, Seeger W, **Günther A**. Safety and tolerability of inhaled heparin in idiopathic pulmonary fibrosis. [J Aerosol Med Pulm Drug Deliv](#) 23(3):161-172, 2010. IF 2,148
- 85) Shetty S, Bhandary YP, Gyetko MR, Cines DB, Idell S, Ruppert C, **Guenther A**, Abraham E, Shetty RS. Induction of Tissue Factor by Urokinase in Lung Epithelial Cells and in the Lungs. [Am J Respir Crit Care Med](#) 181(12):1355-1366, 2010. IF 10,191

- 86) Mahavadi P, Korfei M, Henneke I, Liebisch G, Schmitz G, Gochuico BR, Markart P, Seeger W, Ruppert C*, **Günther A***. Epithelial stress and apoptosis underlie Hermansky-Pudlak syndrome associated interstitial pneumonia. [Am J Respir Crit Care Med](#) 182(2):207-219, 2010. IF 10,191
- 87) Ruppert C, Kuchenbuch T, Boensch M, Schmidt S, Mathes U, Markart P, Reiss I, Schermuly RT, Seeger W, **Günther A**. Dry powder aerosolization of a rSP-C based surfactant for inhalative treatment of the acutely inflamed lung. [Critical Care Med](#) 38(7):1584-1591, 2010. IF 6,254
- 88) Nikolova S, **Günther A**, Savai R, Weissmann N, Ghofrani HA, Königshoff M, Eickelberg O, Klepetko W, Voswinckel R, Seeger W, Grimminger F, Schermuly RT, Pullamsetti SS. Phosphodiesterase 6 subunits are expressed and altered in idiopathic pulmonary fibrosis. [Respir Res](#) 11(1):146, 2010. IF 3,130
- 89) Hoepfer MM, Andreas S, Bastian A, Claussen M, Ghofrani HA, Gorenflo M, Grohé C, **Günther A**, Halank M, Hammerl P, Held M, Krüger S, Lange TJ, Reichenberger F, Sablotzki A, Staehler G, Stark W, Wirtz H, Witt C, Behr J; German Society of Cardiology (DGK), the German Society of Respiratory Medicine (DGP) and the German Society of Pediatric Cardiology (DGPK). Pulmonary hypertension due to chronic lung disease. Recommendations of the Cologne Consensus Conference 2010. [Dtsch Med Wochenschr](#) 135(3):115-124, 2010. IF 0,5
- 90) Spragg R*, Taut F*, Lewis J, Schenk P, Ruppert C, Dean N, Krell K, Karabinis A, **Günther A**. Recombinant surfactant protein C based surfactant for patients with severe direct lung injury. [Am J Respir Crit Care Med](#) 183(8):1055-1061, 2011. IF 11,08
- 91) Beck-Broichsitter M, Ruppert C, Schmehl T, **Günther A**, Betz T, Bakowsky U, Seeger W, Kissel T, Gessler T. Biophysical investigation of pulmonary surfactant surface properties upon contact with polymeric nanoparticles in vitro. [Nanomedicine](#) 7(3):341-350, 2011. IF 3,13
- 92) Pfaff E, Becker S, **Günther A**, Königshoff M. Dickkopf proteins influence epithelial cell proliferation in idiopathic pulmonary fibrosis. [Eur Respir J](#) 37(1):79-87, 2011. IF 5,895
- 93) Avcuoglu S, Wygrecka M, Marsh LM, **Günther A**, Seeger W, Weissmann N, Fink L, Morty R, Kwapiszewska G. The TrkB/NT4 signaling axis is perturbed in clinical and experimental pulmonary fibrosis. [Am J Respir Cell Mol Biol](#) 45(4):768-780, 2011. IF 5,125
- 94) Plantier L, Crestani B, Wert S, Dehoux M, Zweytick B, **Günther A**, Whitsett J. Ectopic respiratory epithelial cell differentiation in bronchiolized distal airspaces in idiopathic pulmonary fibrosis. [Thorax](#) 66(8):651-657, 2011. IF 6,84
- 95) Korfei M, Schmitt S, Ruppert C, Henneke I, Markart P, Loeh B, Mahavadi P, Wygrecka M, Klepetko W, Fink L, Bonniaud P, Preissner K, Lochnit G, Schaefer L, Seeger W, **Günther A**. Comparative proteomic analysis of lung tissue from patients with idiopathic pulmonary fibrosis (IPF) and lung transplant donor lungs. [J Proteome Res](#) 10(5):2185-2205, 2011. IF 5,113
- 96) Wygrecka M, Kwapiszewska G, Jablonska E, von Gerlach S, Henneke I, Zakrzewicz D, **Günther A**, Preissner KT, Markart P. Role of protease-activated receptor-2 in idiopathic pulmonary fibrosis. [Am J Respir Crit Care Med](#) 183(12):1703-1714, 2011. IF 11,08
- 97) Wygrecka M, Wilhelm J, Jablonska E, Zakrzewicz D, Preissner KT, Seeger W, **Günther A**, Markart P. Shedding of low density lipoprotein receptor-related protein-1 in acute respiratory distress syndrome. [Am J Respir Crit Care Med](#) 184(4):438-448, 2011. IF 11,08
- 98) Pullamsetti S, Savai R, Dumitrascu R, Dahal BK, Wilhelm J, Königshoff M, Zakrzewicz D, Ghofrani HA, Weissmann N, Eickelberg O, **Günther A**, Leiper J, Seeger W, Grimminger F, Schermuly RT. The role of dimethylarginine dimethylaminohydrolase in idiopathic pulmonary fibrosis. [Sci Transl Med](#) 3(87):87ra53, 2011. IF 7,804
- 99) Kessler S, Clauss WG, **Günther A**, Kummer W, Fronius M. Expression and functional characterization of P2X receptors in mouse alveolar macrophages. [Pflugers Arch](#) 462(3):419-430; 2011. IF 4,463
- 100) Hoepfer MM, Andreas S, Bastian A, Claussen M, Ghofrani HA, Gorenflo M, Grohé C, **Günther A**, Halank M, Hammerl P, Held M, Krüger S, Lange TJ, Reichenberger F, Sablotzki

- A, Staehler G, Stark W, Wirtz H, Witt C, Behr J. Pulmonary hypertension due to chronic lung disease. [Pneumologie](#) 65(4):208-218, 2011.
- 101) Hoepfer MM, Andreas S, Bastian A, Claussen M, Ghofrani HA, Gorenflo M, Grohé C, **Günther A**, Halank M, Hammerl P, Held M, Krüger S, Lange TJ, Reichenberger F, Sablotzki A, Staehler G, Stark W, Wirtz H, Witt C, Behr J. Pulmonary hypertension due to chronic lung disease: Update Recommendations of the Cologne Consensus Conference 2011. [Int J Cardiol](#) 154 Suppl 1:S45-S53, 2011. IF 7,078
 - 102) Taut F, Bothe G, Schenk P, Dean N, Krell K, **Günther A**, Lewis J, Spragg R. Strategies for Achieving the Goals of a Lung-Protective Ventilation Protocol in Large Clinical Trials. [J Clin Trials](#) 2011 December 5 online. IF 2,12
 - 103) Huang Y, Buscop-van Kempen M, Boerema-de Munck A, Swagemakers S, Driegen S, Meijer D, van IJcken W, van der Spek P, Grosveld F, Mahavadi P, **Günther A**, Tibboel D, Rottier RJ. The hypoxia inducible factor 2 α plays a critical role in the formation of alveoli and surfactant. [Am J Respir Cell Mol Biol](#) 46(2):224-232, 2012. IF 4,148
 - 104) Wells AU, Behr J, Costabel U, Cottin V, Poletti V, Richeldi L, European IPF Consensus Group. Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good. [Thorax](#) 67(11):938-940; 2012. IF 8,376
 - 105) Hoepfer MM, Halank M, Wilkens H, **Günther A**, Weimann G, Gebert I, Leuchte H, Behr J. Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial. [Eur Respir J](#). 41(4):853-860, 2013. IF 7,125
 - 106) Buchwald M, Pietschmann K, Brand P, **Günther A**, Mahajan NP, Heinzl T, Krämer OH. SIAH ubiquitin ligases target the nonreceptor tyrosine kinase ACK1 for ubiquitinylation and proteasomal degradation. [Oncogene](#) 32(41):4913-4920, 2013. IF 8,559
 - 107) Wettstein G, Bellave PS, Kolb M, Hammann A, Crestani B, Soler P, Marchal-Somme J, Hazoume A, Gauldie J, **Günther A**, Micheau O, Gleave M, Camus P, Garrido C, Bonniaud P. Inhibition of HSP27 blocks fibrosis development and EMT features by promoting Snail degradation. [FASEB J](#) 27(4):1549-1560, 2013. IF 5,48
 - 108) Behr J*, **Günther A***, Ammenwerth B, Bittmann I, Bonnet R, Buhl R, Eickelberg O, Ewert R, Gläser S, Gottlieb J, Grohé C, Kreuter M, Kroegel C, Markart P, Neurohr C, Pfeifer M, Prasse A, Schönfeld N, Schreiber J, Sitter H, Theegarten D, Theile A, Wilke A, Wirtz H, Witt C, Worth H, Zabel P, Kauschka D, Kauschka L, Zühl P, Müller-Quernheim J*, Costabel U*. Leitlinien zur Diagnostik und Therapie der idiopathischen Lungenfibrose. [Pneumologie](#) 67(2):81-111, 2013.
 - 109) Janssen W, Pullamsetti SS, Cooke J, Weissmann N, **Günther A**, Schermuly RT. The role of dimethylarginine dimethylaminohydrolase (DDAH) in pulmonary fibrosis. [J Pathol](#) 229(2):242-249, 2013. IF 7,33
 - 110) Conte E, Gili E, Fruciano M, Korfei M, Fagone E, Iemmolo M, Lo Furno D, Giuffrida R, Crimi N, **Günther A**, Vancheri C. P13K p110 γ overexpression in IPF lung tissue and fibroblast cells: Inhibition effects. [Lab Invest](#) 93(5):566-576, 2013. IF 3,828
 - 111) Kosanovic D, Dahal BK, Wygrecka M, Reiss I, **Günther A**, Ghofrani HA, Weissmann N, Grimminger F, Seeger W, Schermuly RT, Banat GA. Mast cell Chymase: an indispensable instrument in the pathological symphony of idiopathic pulmonary fibrosis?. [Histol Histopathol](#) 28(6):691-699, 2013. IF 2,236
 - 112) Aumiller V, Balsara N, Wilhelm J, **Günther A**, Königshoff M. WNT/b-catenin signaling induces interleukin 1b production by alveolar epithelial cells in pulmonary fibrosis. [Am J Res Cell Mol Biol](#) 49(1):96-104; 2013. IF 4,109
 - 113) Ulm C, Saffarzadeh M, Mahavadi P, Müller S, Prem G, Saboor F, Simon P, Middendorf R, Geyer H, Henneke I, Bayer N, Rinné S, Lütteke T, Böttcher-Friebertshäuser E, Gerardy-Schahn R, Schwarzer D, Mühlhoff M, Preissner KT, **Günther A**, Geyer R, Galuska SP. Soluble Polysialylated NCAM: A Novel Player of the Innate Immune System in the Lung. [Cell Mol Life Sci](#). 70(19):3695-708; 2013. IF 5,856
 - 114) Korfei M, Henneke I, Markart P, von der Beck D, Ruppert C, Mahavadi P, Klepetko W, Fink L, Meiners S, Krämer O, Seeger W, Vancheri C, **Günther A**. Comparative Proteome Analysis

- of Lung Tissue from Patients with Idiopathic Pulmonary Fibrosis (IPF), Non-specific Interstitial Pneumonia (NSIP) and Organ Donors. [J Proteomics](#) 85:109-28; 2013. IF 3,929
- 115) Nkyimbeng T, Ruppert C, Shiomi T, Dahal B, Lang G, Seeger W, Okada Y, D'Armiento J, **Günther A**. Pivotal role of Matrix Metalloproteinase 13 in extracellular matrix turnover in Idiopathic Pulmonary Fibrosis. [PLoS One](#). 8(9):e73279; 2013. IF 3,534
- 116) Beck-Broichsitter M, Ruppert C, Schmehl T, **Günther A**, Seeger W. Biophysical inhibition of synthetic vs. naturally-derived pulmonary surfactant preparations by polymeric nanoparticles. [Biochim Biophys Acta](#). 1838(1):474-81; 2013. IF 4,66
- 117) Raghu G, Million-Rousseau R, Morganti A, Perchenet L, Behr J; MUSIC Study Group. Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomized controlled MUSIC trial. [Eur Respir J](#) 42(6):1622-32; 2013. IF 7,125
- 118) Peters DM, Vadász I, Wujak L, Olschewski A, Wygrecka M, Herold S, Mayer K, Rummel S, Brandes RP, **Günther A**, Waldegger S, Eickelberg O, Seeger W, Morty RE. TGF- β directs ENaC trafficking: implications for disturbed alveolar ion and fluid transport in acute lung injury. [PNAS](#). 111(3):E374-83; 2014. IF 9,74
- 119) Varma S, Mahavadi P, Sasikumar S, Cushing L, Hyland T, Rosser A, Riccardi D, Lu J, Kalin T, Kalinichenko V, **Günther A**, Ramirez M, Pardo A, Selman M, Warburton D. Grainyheadlike 2 Distribution Reveals Novel Pathophysiological Differences between Human Idiopathic Pulmonary Fibrosis and Mouse Models of Pulmonary Fibrosis. [Am J of Physiology](#) 306(5):L405-19; 2014. IF 5,645
- 120) Carraro G, Shrestha A, Rostkiovius J, Contreras A, Chao CM, El Agha E, MacKenzie B, Dilai S, Guidolin D, Taketo MM, **Günther A**, Kumar M, Seeger W, De Langhe S, Baretto G, Bellusci S. miR-142-3p balances proliferation and differentiation of mesenchymal cells during lung development. [Development](#) 141(6):1272-81; 2014. IF 6,273
- 121) Frommer KW, Neumann E, Lange U, **Günther A**, Müller-Ladner U. Adipokine und Knochenstoffwechsel – gibt es einen Link? [Aktuelle Rheumatologie](#) 39:375-383; 2014. IF 0,056
- 122) Beck-Broichsitter M, Ruppert C, Schmehl T, **Günther A**, Seeger W. Biophysical inhibition of pulmonary surfactant function by polymeric nanoparticles: Role of surfactant protein B and C. [Acta Biomaterialia](#) 10(11):4678-84; 2014. IF 5,684
- 123) Mahavadi P, Henneke I, Ruppert C, Knudsen L, Venkatesan S, Liebisch G, Chambers RC, Ochs M, Schmitz G, Vancheri C, Seeger W, Korfei M, **Günther A**. Altered surfactant homeostasis and alveolar epithelial cell stress in amiodarone induced lung fibrosis. [ToxSci](#) 142(1):285-97; 2014. IF 4,478
- 124) Chillappagari S, Venkatesan S, Garapati V, Mahavadi P, Munder A, Seubert A, Sarode G, **Günther A**, Schmeck B, Tümmler B, Henke M. Impaired TLR4 and HIF expression in cystic fibrosis bronchial epithelial cells downregulates hemeoxygenase-1 and alters iron homeostasis in vitro. [AJP Lung Cell Mol Physiol](#), 307(10):L791-9; 2014. IF 4,041
- 125) Melboucy-Belkhir S, Pradère P, Tadbiri S, Habib S, Bacrot A, Brayer S, Mari B, Besnard V, Mailleux A, **Günther A**, Castier Y, Mal H, Crestani B, Plantier L. Forkhead Box F1 (FOXF1) represses cell growth, COL1 and ARPC2 expression in lung fibroblasts in vitro. [AJP Lung Cell Mol Physiol](#) 307(11):L838-47; 2014. IF 4,041
- 126) Loeh B, Drakopanagiotakis F, Bandelli GP, von der Beck D, Tello S, Cordani E, Rizza E, Barrocu L, Markart P, Seeger W, **Günther A**, Albera C*. Intraindividual response to treatment with pirfenidone in Idiopathic Pulmonary Fibrosis (IPF). [Am J Respir Crit Care Med](#) 191(1):110-3; 2014. IF 11,986
- 127) Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR; INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. [N Engl J Med](#), 370(22):2071-82; 2014. IF 55,873
- 128) Lutz D, Gazdhar A, Lopez-Rodriguez E, Ruppert C, Mahavadi P, **Günther A**, Klepetko W, Bates JH, Smith B, Geiser T, Ochs M, Knudsen L. Alveolar derecruitment and collapse

- induration as crucial mechanisms in lung injury and fibrosis. [Am J Respir Cell Mol Biol](#) 52(2):232-43; 2015. IF 4,109
- 129) MacKenzie BA, Henneke I, Hezel S, Al Alam D, El Agha E, Chao CM, Quantius J, Wilhelm J, Jones M, Goth K, Li X, Seeger W, Königshoff M, Herold S, **Günther A**, Rizvanov A, Bellusci S. Attenuating endogenous Fgfr2b ligands during Bleomycin-induced lung fibrosis does not compromise murine lung repair. [Am J Physiology Lung Cell Mol Phys](#), 308(10):L1014-24; 2015. IF 4,08
- 130) Oruqaj G, Karnati S, Vijayan V, Kanth L, Boateng E, Zhang W, Ruppert C, **Günther A**, Shi W, Baumgart-Vogt E. Compromised peroxisoms in idiopathic pulmonary fibrosis – a vicious cycle inducing a higher fibrotic response via TGF-β1 signaling. [PNAS](#), 112(16):E2048-57; 2015. IF 9,674
- 131) Keller IE, Vosyka O, Takenaka S, Kloß A, Dahlmann B, Willems LI, Verdoes M, Overkleeft HS, Marcos E, Adnot S, Hauck SM, Ruppert C, **Günther A**, Ohno S, Adler H, Eickelberg O, Meiners S. Regulation of Immunoproteasome Function in the lung. [Scientific Reports](#), 9:10230; 2015. IF 5,578
- 132) Mahavadi P, Knudsen L, Venkatesan S, Henneke I, Hegermann J, Wrede C, Ochs M, Ahuja S, Chillappagari S, Ruppert C, Seeger W, Korfei M, **Günther A**. Regulation of macroautophagy in amiodarone-induced pulmonary fibrosis. [J Pathol Clin Research](#), 1(4):252-63; 2015. IF 7,429
- 133) Birkelbach B, Lutz D, Ruppert C, Henneke I, Lopez-Rodriguez E, **Günther A**, Ochs M, Mahavadi P*, Knudsen L*. Linking progression of fibrotic lung remodeling and ultrastructural alterations of alveolar epithelial type II cells in the amiodarone mouse model. [Am J Physiology Lung Cell Mol Phys](#), 309(1):L63-75; 2015. IF 4,08
- 134) Chillappagari SP, Preuss J, Licht S, Müller C, Mahavadi P, Sarode G, Vogelmeier C, **Günther A**, Nährlich L, Rubin BK, Henke MO. Altered protease and antiprotease balance in COPD sputum during pulmonary exacerbation contributes to mucus accumulation. [Respiratory Research](#), 16(1):85; 2015. IF 3,093
- 135) Semren N, Welk V, Korfei M, Fernandez I, **Günther A**, Eickelberg O, Meiners S. Regulation of 26S proteasome activity in pulmonary fibrosis. [AJRCCM](#), 192(9):1089-101; 2015. IF 12,996
- 136) MacKenzie B, Korfei M, Henneke I, Sibinska Z, Tian X, Hezel S, Dilai S, Wasnick R, *Schneider B, Wilhelm J, El Agha E, Klepetko W, Seeger W, Schermuly R, Günther A*, Belusci S. Increased FGF1-FGFRc expression in idiopathic pulmonary fibrosis. [Respiratory Research](#), 16:83; 2015. IF 3,093
- 137) Knippenberg S, Ueberberg B, Maus R, Bohling J, Ding N, Tarres MT, Hoymann HG, Jonigk D, Izykowski N, Paton J, Ogunniyi A, Lindig S, Bauer M, Welte T, Seeger W, **Günther A**, Sisson, TH, Gauldie J, Kolb M, Maus U. Streptococcus pneumonia triggers progression of pulmonary fibrosis through pneumolysin. [Thorax](#), 70(7):636-46; 2015. IF 8,29
- 138) Korfei M, Skwarna S, Henneke I, MacKenzie B, Klymenko O, Saito S, Ruppert C, von der Beck D, Mahavadi P, Klepetko W, Bellusci S, Crestani B, Pullamsetti S, Fink L, Seeger W, Krämer O*, **Günther A***. Aberrant expression and activity of histone deacetylases in sporadic idiopathic pulmonary fibrosis. [Thorax](#), 70(11):1022-32; 2015. IF 8,39
- 139) Kreuter M, Herth FJF, Wacker M, Leidl R, Hellmann A, Pfeifer M, Behr J, Witt S, Kauschka D, Mall MA, **Günther A**, Markart P. Exploring clinical and epidemiological characteristics of interstitial lung diseases (EXCITING-ILD). [BioMed Research International](#), Oktober 2015. IF 3,169
- 140) Chillappagari SP, Müller C, Mahavadi P, **Günther A**, Nährlich L, Rosenblum J, Rubin B. A small molecule neutrophil elastase inhibitor, KRP-109, inhibits cystic fibrosis mucin degradation. [Journal of Cystic Fibrosis](#). S1569-1992(15); 2015. IF 3,475
- 141) Behr J, Bonella F, Bonnet R, Gläser S, Grohé C, **Günther A**, Koschel D, Kreuter M, Kirsten D, Krögel C, Markart P, Müller-Quernheim J, Neurohr C, Pfeifer M, Prasse A, Schönfeld N, Schreiber J, Wirtz H, Witt C, Costabel U. Position Paper: Significance of the Forced Vital Capacity in Idiopathic Pulmonary Fibrosis. [Pneumologie](#). 69(8):455-8; 2015. IF 0,0

- 142) Ahuja S, Knudsen L, Chillappagari S, Henneke I, Ruppert C, Korfei M, Gochuico BR, Bellusci S, Seeger W, Ochs M, **Günther A***, Mahavadi P*. MAP1LC3B overexpression protects against Hermansky-Pudlak syndrome type - 1 induced defective autophagy in vitro. [AJP Lung](#). Epub Dezember 2015. IF 4,041
- 143) Behr J, Bendstrup E, Crestani B, **Günther A**, Olschewski H, Sköld M, Wells A, Wuyts W, Koschel D, Kreuter M, Wallaert B, Lin CY, Beck J, Albera C. The safety and tolerability of N-acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled trial. [Lancet Respiratory](#). 4(6):445-453; 2016. IF 9,629
- 144) White ES, Borok Z, Brown KK, Eickelberg O, **Günther A**, Jenkins RG, Kolb M, Martinez FJ, Roman J, Sime P. An American Thoracic Society Official Research Statement: Future direction in Lung Fibrosis research. [Am J Respir Crit Care Med](#). 193(7):792-800; 2016. IF 12,996
- 145) Mehta A, Cordero J, Dobersch S, Romero-Olmedo A, Savai R, Bodner J, Chao CM, Fink L, Guszman-Diaz E, Singh I, Dobrova G, Rapp UR, Günther S, Ilnskaya ON, Bellusci S, Damman R, Braun T, Seeger W, Gattenlöhner S, Tresch A, **Günther A**, Barreto G. Non-invasive lung cancer diagnosis by detection of GATA6 and NKX2-1 isoforms in exhaled breath condensate. [EMBO Molecular Medicine](#), 8(12):1380-89; 2016. IF 8,46
- 146) Sibinska Z, Tian X, Korfei M, Kojonazarov B, Kolb J, Klepetko W, Konsanovic D, Wygrecka M, Ghofrani HA, Weissmann N, Grimminger F, Seeger W, **Günther A**, Schermuly R. Amplified canonical TGF- β signaling via heat shock protein 90 in Pulmonary Fibrosis. [European Respiratory Journal](#). In press; September 2016. IF 2,18
- 147) El Agha E, Moiseenko A, Kheirollahi V, De Langhe S, Crnkovic S, Kwapiszewska G, Kosanovic D, Schwind F, Scheruly R, Hennecke I, MacKenzie B, Quantius J, Herold S, Ntokou A, Ahlbrecht K, Morty R, Guenther A, Seeger W, Bellusci S. Two-Way Conversion between Lipogenic and Myogenic Fibroblastic Phenotypes Marks the Progression and Resolution of Lung Fibrosis. [Cell Stem Cell](#), S1934-5909(16):30344-7; 2016. IF 15,05
- 148) Baarsma HA, Skronska-Wasek W, Mutze K, Ciolek F, Wagner DE, John-Schuster G, Heinzelmann K, **Günther A**, KR Bracke, Dagouassat M, Boczkowski J, Brusselle GG, Smits R, Eickelberg O, Yildirim AÖ, Königshoff M. Non-canonical WNT-5A signaling impairs endogenous lung repair in COPD. [Journal of Experimental Medicine](#). In Press; Dezember 2016. IF 8,69
- 149) Zhang R, Wu L, Eckert T, Burg-Roderfeld M, Rojas-Macias MA, Lütteke T, Krylov VB, Argunov DA, Datta A, Markart P, **Günther A**, Norden B, Schauer R, Bhunia A, Enani MA, Billeter M, Scheidig AJ, Nifantiev NE, Siebert H-C. Lysozyme's Lectin-like Characteristics Facilitates its Immune Defense Function. [Quarterly Reviews of Biophysics](#). 50-c9; 2017. IF 13,27

*beide Autoren haben in gleichem Umfang zu der Veröffentlichung beigetragen

Korrespondenz/Letters to the Editor

- 1) Münster AB, Gram J, Sidelmann J, **Günther A**, Idell S. Aerosolized Urokinase in Pulmonary Fibrosis. **Letter** to the Editor. [Am J Respir Crit Care Med](#) 169:1258-1259, 2004. IF 9,074
- 2) **Guenther A**, Eickelberg O, Preissner KT, Chambers R, Laurent G, Wells A, Crestani B, Vancheri B, Bonniaud P, Camus P, Schmitz G, Klepetko W, Schultze J, Vossmeier D, Stumpf P. International registry for idiopathic pulmonary fibrosis. Letter to the Editor. [Thorax](#) 63:841, 2008. IF 7,096
- 3) **Günther A**, Taut F. Tidal volume in mechanical ventilation: The importance of considering predicted body weight. Letter to the Editor. [Am J Respir Crit Care Med](#) 178:315-316, 2008. IF 9,792

Reviews / Editorials / Kommentare

- 1) Seeger W, **Günther A**, Walmrath HD, Grimminger F, Lasch HG. Alveolar surfactant and adult respiratory distress syndrome. Pathogenetic role and therapeutic prospects. [Clinical Investigator](#) 71:177-190, 1993. IF 8,519
- 2) **Günther A**, Elssner A, Kalinowski M, Seeger W; The inactivation of surfactant by proteins. [Lung & Respiration](#) 11 (special issue):11-23, 1994. IF 1,017
- 3) Seeger W, **Günther A**, Walmrath D, Schmidt R, Grimminger F. Surfactanttherapie des ARDS - Hintergrund und erste klinische Erfahrungen. [Atemw.- und Lungenkrh](#) 22, 1996.
- 4) **Günther A** Kommentar zu „Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. N Engl J Med 334:1417-1421“ in: [Pneumologie](#) 50:769, 1996.
- 5) **Günther A** Kommentar zu „Primary importance of zwitterionic over anionic phospholipids in the surface-active function of calf lung surfactant, Am J Respir Crit Care Med 156:1049-1057, 1997“ in: [Pneumologie](#) 52:639, 1998.
- 6) **Günther A**, Walmrath D, Grimminger F, Seeger W. Pathophysiology of Acute Lung Injury. [Seminars Respir Crit Care Med](#) 22:247-258, 2001. IF 1,225
- 7) **Günther A**, Ruppert C, Schmidt R, Markart P, Grimminger F, Walmrath D, Seeger W. Surfactant alteration and replacement in acute respiratory distress syndrome. [Respir Res](#) 2:353-364, 2001. IF 2,353
- 8) Frerking U, **Günther A**, Seeger W, Pison U. Pulmonary surfactant: functions, abnormalities and therapeutic options. [Intens Care Med](#) 27:1699-1717, 2001. IF 4,406
- 9) **Günther A**, Ermert L, Breithecker A, Hackstein N, Eickelberg O, Morr H, Grimminger F, Velcovsky HG, Seeger W. Klassifikation, Diagnostik und Therapie der Idiopathischen Interstitiellen Pneumonien. [Dt Ärzteblatt](#) 100:A1676- A1685, 2003. IF 2,9
- 10) Markart P, Hundack L, Ghofrani A, Grimminger F, Seeger W, **Günther A**. Idiopathische Interstitielle Pneumonien: Pathomechanismen und Therapieoptionen. [Pneumologie](#) 59:554-561, 2005. IF 2,251
- 11) **Günther A**, Markart P, Eickelberg O, Seeger W. Pulmonary Fibrosis – a therapeutic dilemma? [Med Klin](#) 101:308-312, 2006. IF 0,289
- 12) Markart P, Seeger W, **Günther A**. Differential therapy of pulmonary fibrosis. [Internist](#) 47:S26-S32, 2006. IF 0,277
- 13) Markart P, Breithecker A, Bohle RM, Seeger W, **Günther A**. Klinische, radiologische und histopathologische Kriterien zur differentialdiagnostischen Abgrenzung der exogen-allergischen Alveolitis und der nicht-spezifischen interstitiellen Pneumonie. [Allergologie](#) 29:470-475, 2006. IF 0,237
- 14) Ruppert C, Markart P, Wygrecka M, Preissner KT, **Günther A**. Role of coagulation and fibrinolysis in lung and renal fibrosis. [Hämostaseologie](#) 28:30-36, 2008. IF 5,987
- 15) Markart P, **Günther A**. Kommentar zu “Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 356:1317-1326, 2007” in: [Pneumonews](#) 1:27, 2007.
- 16) Markart P, **Günther A**. Kommentar zu “Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med 176:277-284, 2007” in: [Pneumonews](#) 1:38, 2007.
- 17) **Günther A**. Perspektiven der Therapie fibrosierender Lungenerkrankungen – PMS Symposium: Perspektiven der pneumologischen Pharmakotherapie. [Arzneim-Forsch \(Drug Res\)](#) 57:736-737, 2007. IF 0,692
- 18) Markart P, **Günther A**. Kommentar zu “Idiopathic Nonspecific Interstitial Pneumonia. Lung Manifestation of Undifferentiated Connective Tissue Disease? Am J Respir Crit Care Med 176; 691-697, 2007” in: [Pneumonews](#) 1:32, 2008.

- 19) Markart P, **Günther A**. Kommentar zu "BUILD-1: A randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 177:75-81, 2008" in: [PneumoneWS](#) 2:32-33, 2008.
- 20) Markart P, **Günther A**. Kommentar zu "Idiopathic Pulmonary Fibrosis. Outcome in Relation to Smoking Status. Am J Respir Crit Care Med 177:190-194, 2008" in: [PneumoneWS](#) 3:14-15, 2008.
- 21) Wygrecka M, Jablonska E, **Günther A**, Preissner KT, Markart P. Current view on alveolar coagulation and fibrinolysis in acute inflammatory and chronic interstitial lung diseases. [Thromb Haemost](#) 99:494-501, 2008. IF 3,501
- 22) Ruppert C, Seeger W, **Günther A**. Surfactant in ARDS. [The Lung Perspectives](#) 16:6-73 2008.
- 23) Markart P, **Günther A**. Kommentar zu „Modulation of bleomycin-induced lung fibrosis by serotonin receptor antagonists in mice. Eur Respir J 32:426-36, 2008" in: [PneumoneWS](#) 5:32, 2008.
- 24) Markart P, **Günther A**. Kommentar zu „Short telomers are a risk factor for idiopathic pulmonary fibrosis. PNAS 105:13051-13056, 2008" in: [PneumoneWS](#) 6:33, 2008.
- 25) Markart P, **Günther A**. Kommentar zu „Seasonal variation: Mortality from pulmonary fibrosis is greatest in the winter. Chest 2008" in: [PneumoneWS](#) 3:19, 2009.
- 26) Markart P, **Günther A**. Kommentar zu „Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 179:717-23, 2009" in: [PneumoneWS](#) 4:27, 2009.
- 27) Markart P, **Günther A**. Kommentar zu "Idiopathic pulmonary fibrosis and emphysema. Decreased survival associated with severe pulmonary arterial hypertension. Chest 136:10-15, 2009" in: [PneumoneWS](#) 5:24, 2009.
- 28) Markart P, **Günther A**. Differenzialdiagnostik der Lungenfibrose „Das ganze Spektrum erkennen". [PneumoneWS](#) 6:40, 2009.
- 29) Markart P, **Günther A**. Kommentar zu „Survival after bilateral versus single-lung transplantation for idiopathic pulmonary fibrosis. Ann Intern Med 151:767-774, 2009" in: [PneumoneWS](#) 1:22-23, 2010.
- 30) Markart P, Ghofrani HA, Grimminger F, **Günther A**. Pulmonary hypertension in COPD and interstitial lung disease. [Dtsch Med Wochenschr](#) 134 Suppl 5:164-166, 2009. IF 0,590
- 31) Markart P, **Günther A**. Kommentar zu „Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1). Eur Respir J 35:118-123, 2010" in: [PneumoneWS](#) 2:22-23, 2010.
- 32) Markart P, **Günther A**. Kommentar zu „Imatinib treatment for idiopathic pulmonary fibrosis. Randomized placebo-controlled trial results. Am J Respir Crit Care Med 181:604-610, 2010" in: [PneumoneWS](#) 3:20-21, 2010.
- 33) Markart P, **Günther A**. Kommentar zu „A controlled trial of Sildenafil in advanced Idiopathic Pulmonary Fibrosis. N Eng J Med 363:620-628, 2010" in: [PneumoneWS](#) 4:13, 2010.
- 34) Markart P, **Günther A**. Kommentar zu „Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 35:1322-1328, 2010" in: [PneumoneWS](#) 5:22-24, 2010.
- 35) Markart P, Wygrecka M, **Guenther A**. Update in diffuse parenchymal lung disease 2010. [Am J R Crit Care Med](#) 183(10):1316-1321, 2011. IF 10,689
- 36) **Guenther A**. The European IPF Network: towards better care for a dreadful disease. [Eur Respir J](#) 37:747-748; 2011. IF 5,527
- 37) von der Beck D, **Günther A**, Markart P. Interstitial lung disease. [Dtsch Med Wochenschr](#) 136:1191-1193, 2011. IF 0,590

- 38) Mahavadi P, **Günther A**, Gochuico BR. Hermansky-Pudlak Syndrome Interstitial Pneumonia: It's the Epithelium, Stupid! [Am J Respir Crit Care Med](#) 186(10):939-940, 2012. IF 5,125
- 39) **Günther A**, Korfei M, Mahavadi P, von der Beck D, Ruppert C, Markart P. Unravelling the progressive pathophysiology of IPF. [Eur Respir Rev](#) 21(124):152-160, 2012. IF 5,895
- 40) Von der Beck D, Wygrecka M, **Günther A***, Markart P*. Pirfenidon. [Arzneimittel-,Therapie-Kritik](#) Oktober 2012.
- 41) Von der Beck D, Markart P, Seeger W, **Günther A**. Die Therapie der idiopathischen pulmonalen Fibrose – Besonderheiten und Komplikationen. [Der Pneumologe](#) 10(2):105-111, 2013.
- 42) Costabel U, Albera C, Behr J, Cotin V, **Günther A**, Richeldi L. Idiopathic pulmonary fibrosis in 2011: key updates on guidelines and therapeutics. [Respir Res](#). 14 Suppl 1:S1; 2013. IF 3,130
- 43) von der Beck D, Löh B, Drakopanagiotakis F, Markart P, **Günther A**. Antifibrotische Therapien. [Dtsch Med Wochenschr](#) 139(49):2523-2525; 2014. IF 0,653
- 44) Grimminger F, **Günther A**, Vancheri C. The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis. [Eur Respir J](#). 45(5):1426-33 IF 7,636
- 45) Loeh B, Korfei M, Mahavadi P, Wasnick R, von der Beck D, **Günther A**. Pathogenesis of Idiopathic Pulmonary Fibrosis. [ERS Monograph](#) Dezember 2015.
- 46) Markart P, **Günther A**. Kommentar zu „Genvarianten beeinflussen das Ansprechen auf eine IPF-Therapie mit N-Acetylcystein“. [Am J Respir Crit Care Med](#) 192(12):1475; 2015 in: [Pneumonews](#) 8(1):23; 2016.
- 47) Korfei M, Ruppert C, Löh B, Mahavadi P, **Günther A**. The role of Endoplasmic Reticulum (ER) stress in pulmonary fibrosis. [Endoplasmic Reticulum in Disease](#) 3(1):16-49; 2016.

Buchbeiträge

- 1) **Günther A**, Grube C, Seeger W. Inhibition of surfactant by plasma proteins; in: [Surfactant in clinical practice](#) (G. Bevilaqua, S. Parmigiani, B. Robertson, Ed.), Harwood Academic Publishers; Chur, Switzerland; 87-102, 1992.
- 2) Seeger W, **Günther A**. Surfactant and adult respiratory distress syndrome; in: [Progress in Respiration Research: Lung Surfactant: Basic research in the pathogenesis of lung disorders](#). (H. Herzog, Ed.). Karger Basel 222-231, 1994.
- 3) **Günther A**, Seeger W. Resistance to surfactant inactivation; in: [Surfactant Therapy for Lung Disease](#) (B. Robertson und H. W. Taeusch, Ed.) Marcel Dekker, New York, 269-292, 1995.
- 4) **Günther A**, Walmrath D, Grimminger F, Seeger W. Alteration of pulmonary surfactant in adult respiratory distress syndrome: effects of a transbronchial surfactant application; in: [Advances in perinatal medicine](#) (F. Cockburn, Ed.). Parthenon Publishing Group, New York, London, 328-330, 1997.
- 5) Seeger W, **Günther A**, Walmrath D. Alveolar Surfactant and ARDS; in: [Update in Intensive Care and Emergency Medicine: Acute Lung Injury](#) (J.J. Marini und T. W. Evans, Ed.). Springer Verlag Berlin, Heidelberg, New York, 88-106, 1998.
- 6) **Günther A**, Walmrath D, Grimminger F, Seeger W. Alteration of Pulmonary Surfactant in ARDS - Pathogenetic Role and Therapeutic Perspectives; in: [Acute Respiratory Distress Syndrome: Cellular and Molecular Mechanisms and Clinical Management](#) (S. Matalon und J. I. Sznajder, Ed.). Plenum Press New York, 97-105, 1998.
- 7) Seeger W, **Günther A**. Pulmonary Surfactant; in: [Oxford Handbook of Critical Care Medicine](#) (A. R. Webb, M. J. Shapiro, M. Singer und P. M. Suter, Ed.) Oxford University Press, Oxford, 1280-1282, 1999.

- 8) **Günther A**, Walmrath D, Grimminger F, Grimminger F. Surfactant metabolism and replacement in ARDS; in: [European Respiratory Monograph](#) Vol 7, Monograph 20: Acute Respiratory Distress Syndrome (T.W. Evans, M.J.D. Griffiths and B. F. Keogh, Ed.). European Respiratory Society Sheffield, UK, 119-128, 2002.
- 9) Ruppert C, Seeger W, **Günther A**. Prospects for reduction of ventilator-induced lung injury with surfactant; in: [Lung Biology in Health and Disease](#): Ventilator-induced lung injury (D. Dreyfuss, G. Saumon and R. Hubmayr, Ed.). Taylor & Francis, New York, 2006.
- 10) **Günther A**, Ruppert C. Anticoagulants; in: [Encyclopedia of Respiratory Medicine](#) (G. J. Laurent and S. D. Shapiro, Ed.) Elsevier, Oxford, UK, 2006.
- 11) **Günther A**, Ruppert C. Coagulation Cascade: Fibrinogen and Fibrin; in: [Encyclopedia of Respiratory Medicine](#) (G. J. Laurent and S. D. Shapiro, Ed.) Elsevier, Oxford, UK, 2006.
- 12) **Günther A**, Ruppert C. Coagulation Cascade: Antithrombin III; in: [Encyclopedia of Respiratory Medicine](#) (G. J. Laurent and S. D. Shapiro, Ed.) Elsevier, Oxford, UK, 2006.
- 13) Majeed RW, Kuhn S, Ruppert C, **Günther A**, Röhrig R. Bringing heterogenous Research Data together: Data Protection for the German Centre for Lung Research (DZL). [Stud Health Technol Inform](#). 201:995, 2015.

Lehrbuchkapitel

- 1) Seeger W, **Günther A**. Pulmonary Surfactant; in: [Oxford Handbook of Critical Care Medicine](#) (A. R. Webb, M. J. Shapiro, M. Singer und P. M. Suter, Ed.) Oxford University Press, Oxford. 1280-1282, 1999.
- 2) **A Günther**. Diffus parenchymatöse Lungenerkrankungen, in: [Klinische Pneumologie](#), 4. Auflage (Matthys, Seeger, Hrsg.), Springer Verlag, Heidelberg Berlin. 373-394, 2008.
- 3) **A Günther**, F Grimminger, W Seeger. Interstitielle Lungenerkrankungen, in: [Lehrbuch Innere Medizin](#), 6. Auflage (CDK Classen/Diehl/Kochsiek - Böhm/Hallek/Schmiegel, Hrsg.), Elsevier Verlag, München. 321–333, 2009.
- 4) **Günther A**, von der Beck D, Markart P. Idiopathische Lungenfibrose Diagnostik und Therapie; CME zertifizierte Fortbildung in: [CME mit Partnern, Springer Verlag online](#), 2012.